Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioCryst reports inducement grants under Nasdaq listing rule » 07:16
06/02/20
06/02
07:16
06/02/20
07:16
BCRX

BioCryst

$4.70 /

+0.2 (+4.45%)

BioCryst Pharmaceuticals…

BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 147,500 shares of BioCryst common stock on May 29, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $4.50 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

ShowHide Related Items >><<
BCRX BioCryst
$4.70 /

+0.2 (+4.45%)

BCRX BioCryst
$4.70 /

+0.2 (+4.45%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
BCRX BioCryst
$4.70 /

+0.2 (+4.45%)

BCRX BioCryst
$4.70 /

+0.2 (+4.45%)

BCRX BioCryst
$4.70 /

+0.2 (+4.45%)

Thursday
Syndicate
BioCryst 18.711M share Spot Secondary priced at $4.50 » 06:23
05/28/20
05/28
06:23
05/28/20
06:23
BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

The deal range was…

The deal range was $4.50-$4.85. and Piper Sandler acted as joint book running managers for the offering.

ShowHide Related Items >><<
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

  • 28
    May
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

Over a week ago
On The Fly
Fly Intel: After-Hours Movers » 19:08
05/27/20
05/27
19:08
05/27/20
19:08
NTNX

Nutanix

$24.94 /

+0.53 (+2.17%)

, COHR

Coherent

$149.11 /

+3.8 (+2.62%)

, HPQ

HP Inc.

$17.13 /

+0.06 (+0.35%)

, NTAP

NetApp

$46.30 /

+1.23 (+2.73%)

, ADSK

Autodesk

$199.71 /

+0.28 (+0.14%)

, HTZ

Hertz

$1.31 /

+0.7199 (+122.00%)

, IOVA

Iovance Biotherapeutics

$38.12 /

+0.66 (+1.76%)

, ARNA

Arena Pharmaceuticals

$58.07 /

+1.16 (+2.04%)

, CRNC

Cerence

$33.05 /

+0.47 (+1.44%)

, BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

, IMMU

Immunomedics

$34.18 /

+0.1 (+0.29%)

, PEN

Penumbra

$170.74 /

+1.29 (+0.76%)

, TWTR

Twitter

$33.06 /

-0.96 (-2.82%)

, PLT

Plantronics

$14.66 /

+0.67 (+4.79%)

, IMAB

I-MAB

$23.87 /

+0.665 (+2.87%)

, BA

Boeing

$149.46 /

+4.77 (+3.30%)

, HPP

Hudson Pacific

$24.18 /

+1.06 (+4.59%)

, DHC

Diversified Healthcare Trust

$3.23 /

+0.03 (+0.94%)

, PLMR

Palomar

$65.68 /

+2.57 (+4.07%)

, PHAS

PhaseBio

$4.42 /

-0.03 (-0.67%)

, SPTN

SpartanNash

$20.57 /

-0.02 (-0.10%)

, WDAY

Workday

$170.10 /

+1.72 (+1.02%)

, TOL

Toll Brothers

$32.95 /

+2.835 (+9.42%)

, BGFV

Big 5 Sporting

$1.94 /

+0.06 (+3.19%)

, SMTC

Semtech

$50.13 /

+1.18 (+2.41%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

05/21/20 JPMorgan
Nutanix price target lowered to $24 from $27 at JPMorgan
05/19/20 OTR Global
Nutanix downgraded to Mixed from Positive at OTR Global
04/27/20 Needham
Nutanix price target lowered to $24 from $42 at Needham
04/23/20 Cleveland Research
Nutanix trends in April softened versus prior months, says Cleveland Research
COHR Coherent
$149.11 /

+3.8 (+2.62%)

04/23/20 Goldman Sachs
Coherent upgraded to Buy from Neutral at Goldman Sachs
02/10/20
Fly Intel: Top five analyst initiations
02/10/20 Stifel
Coherent transferred with a Buy, $178 price target at Stifel
02/06/20 Piper Sandler
Coherent price target lowered to $195 from $205 at Piper Sandler
HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

05/26/20 Credit Suisse
HP Inc. price target lowered to $17 from $22 at Credit Suisse
05/22/20 JPMorgan
HP shares worth owning through downturn, says JPMorgan
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
04/21/20 Deutsche Bank
HP Inc. price target lowered to $17 from $20 at Deutsche Bank
NTAP NetApp
$46.30 /

+1.23 (+2.73%)

05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 Stifel
NetApp downgraded to Hold from Buy at Stifel
ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

05/22/20 Deutsche Bank
Autodesk price target lowered to $215 from $230 at Deutsche Bank
05/21/20 Citi
Citi sees difficult setup for Autodesk into results, cuts price target
05/19/20 KeyBanc
Autodesk price target raised to $210 from $200 at KeyBanc
05/07/20 OTR Global
Autodesk downgraded to Mixed from Positive at OTR Global
HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
04/27/20 Piper Sandler
AACR abstract for Moffitt study positive for Iovance, says Piper Sandler
04/22/20 Piper Sandler
AACR meeting should bring more support for Iovance TILs, says Piper Sandler
ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
CRNC Cerence
$33.05 /

+0.47 (+1.44%)

05/27/20 Wedbush
Cerence price target raised to $40 from $27 at Wedbush
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/12/20
Fly Intel: Top five analyst initiations
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
PEN Penumbra
$170.74 /

+1.29 (+0.76%)

05/08/20 Citi
Penumbra price target raised to $214 from $192 at Citi
03/04/20 Citi
Penumbra initiated with a Buy at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/26/20 Canaccord
Penumbra weakness buying opportunity, says Canaccord
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
05/01/20
Fly Intel: Top five analyst downgrades
05/01/20 Deutsche Bank
Twitter price target raised to $28 from $22 at Deutsche Bank
PLT Plantronics
$14.66 /

+0.67 (+4.79%)

04/16/20 Morgan Stanley
Morgan Stanley cuts Plantronics to Underweight citing upcoming challenges
04/16/20 Morgan Stanley
Plantronics downgraded to Underweight from Equal Weight at Morgan Stanley
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
BA Boeing
$149.46 /

+4.77 (+3.30%)

05/22/20 Canaccord
Boeing price target lowered to $155 from $175 at Canaccord
05/20/20 RBC Capital
RBC starts Boeing at Outperform on favorable risk/reward profile
05/20/20 RBC Capital
Boeing initiated with an Outperform at RBC Capital
05/05/20 Nord/LB
Boeing downgraded to Sell from Hold at Nord/LB
HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

04/16/20 Jefferies
Hudson Pacific initiated with a Hold at Jefferies
02/04/20 Mizuho
Hudson Pacific assumed with a Buy at Mizuho
01/15/20 Mizuho
Hudson Pacific upgraded to Buy from Neutral at Mizuho
11/08/19 Goldman Sachs
Hudson Pacific initiated with a Buy at Goldman Sachs
DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

05/19/20 RBC Capital
Diversified Healthcare Trust price target lowered to $3 from $7 at RBC Capital
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
01/16/20 Wells Fargo
Diversified Healthcare Trust cut to Equal Weight from Overweight at Wells Fargo
01/07/20 Raymond James
Healthcare REIT sector downgraded to Market Weight at Raymond James
PLMR Palomar
$65.68 /

+2.57 (+4.07%)

01/14/20 JMP Securities
Palomar price target raised to $55 from $50 at JMP Securities
01/10/20 Keefe Bruyette
Palomar target raised to $58 after share offering at Keefe Bruyette
12/16/19 William Blair
Palomar should be bought despite recent rally, says William Blair
12/08/19 Keefe Bruyette
Palomar price target raised to $57 from $48 at Keefe Bruyette
PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

05/07/20 Stifel
Portola deal highlights value of PhaseBio's PB2452, says Stifel
04/06/20 Citi
PhaseBio price target lowered to $11 from $25 at Citi
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

03/19/20 Barclays
SpartanNash upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
SpartanNash upgraded to Market Perform from Underperform at BMO Capital
10/04/19
SpartanNash management to meet with Loop Capital
WDAY Workday
$170.10 /

+1.72 (+1.02%)

05/21/20 OTR Global
Workday downgraded to Mixed from Positive at OTR Global
05/18/20
Fly Intel: Top five analyst downgrades
05/18/20 Cleveland Research
Workday downgraded to Neutral from Buy at Cleveland Research
05/18/20 RBC Capital
Workday price target lowered to $194 from $230 at RBC Capital
TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

05/27/20 Credit Suisse
Toll Brothers initiated with a Neutral at Credit Suisse
05/27/20 Credit Suisse
KB Home initiated with an Outperform at Credit Suisse
05/11/20 Wedbush
Toll Brothers price target lowered to $35 from $48 at Wedbush
05/04/20 Evercore ISI
Toll Brothers upgraded to In Line from Underperform at Evercore ISI
BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

03/12/20 Susquehanna
Semtech results inline and guidance better than feared, says Susquehanna
03/12/20 Loop Capital
Semtech price target lowered to $46 from $56 at Loop Capital
03/12/20 B. Riley FBR
Semtech price target lowered to $50 from $55 at B. Riley FBR
03/12/20 Needham
Semtech upgraded to Buy from Hold at Needham
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

  • 29
    May
  • 28
    May
  • 28
    May
  • 28
    May
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

Syndicate
BioCryst $100M Spot Secondary; price range $4.50-$4.85 » 16:14
05/27/20
05/27
16:14
05/27/20
16:14
BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

JPMorgan and Piper…

JPMorgan and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

Syndicate
BioCryst announces offering of $100M of common stock » 16:03
05/27/20
05/27
16:03
05/27/20
16:03
BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

BioCryst Pharmaceuticals…

BioCryst Pharmaceuticals announced that it is offering to sell $100Mof its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. J.P. Morgan and Piper Sandler are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

Options
BioCryst call volume above normal and directionally bullish » 12:25
05/20/20
05/20
12:25
05/20/20
12:25
BCRX

BioCryst

$5.47 /

+0.375 (+7.37%)

Bullish option flow…

Bullish option flow detected in BioCryst with 17,937 calls trading, 3x expected, and implied vol increasing almost 6 points to 145.85%. Jul-20 9 calls and Jun-20 7 calls are the most active options, with total volume in those strikes near 11,000 contracts. The Put/Call Ratio is 0.07. Earnings are expected on August 4th.

ShowHide Related Items >><<
BCRX BioCryst
$5.47 /

+0.375 (+7.37%)

BCRX BioCryst
$5.47 /

+0.375 (+7.37%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
BCRX BioCryst
$5.47 /

+0.375 (+7.37%)

BCRX BioCryst
$5.47 /

+0.375 (+7.37%)

BCRX BioCryst
$5.47 /

+0.375 (+7.37%)

Options
BioCryst call volume above normal and directionally bullish » 11:05
05/11/20
05/11
11:05
05/11/20
11:05
BCRX

BioCryst

$5.41 /

+0.725 (+15.49%)

Bullish option flow…

Bullish option flow detected in BioCryst with 10,488 calls trading, 3x expected, and implied vol increasing over 27 points to 190.72%. May-20 4 calls and May-20 5 calls are the most active options, with total volume in those strikes near 5,400 contracts. The Put/Call Ratio is 0.18. Earnings are expected on August 4th.

ShowHide Related Items >><<
BCRX BioCryst
$5.41 /

+0.725 (+15.49%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
Recommendations
BioCryst has potential best-in-class PNH treatment, says JMP Securities » 12:27
05/06/20
05/06
12:27
05/06/20
12:27
BCRX

BioCryst

$3.92 /

-0.03 (-0.76%)

JMP Securities analyst…

JMP Securities analyst Liisa Bayko says BioCryst Pharmaceuticals' Q1 results were headlined by data supporting BCX9930 as a potential best-in-class treatment for paroxysmal nocturnal hemoglobinuria. Oral factor D inhibitor BCX9930 showed an "impressive" improvement in multiple markers of disease in three severe treatment naive PNH patients after just 28 days of dosing with no evidence of the transient rash that occurred in healthy volunteers, Bayko tells investors in a research note. BioCryst's most important 2020 event, according to the analyst, remains the December 3 FDA action data for berotralstat. Bayko keeps an Outperform rating on BioCryst with a $10 price target. The stock in midday trading is down 2% to $3.89.

ShowHide Related Items >><<
BCRX BioCryst
$3.92 /

-0.03 (-0.76%)

05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
03/05/20 Piper Sandler
BioCryst's berotralstat should still be approved this year, says Piper Sandler
Recommendations
BioCryst price target raised to $10 from $8 at Piper Sandler » 11:44
05/06/20
05/06
11:44
05/06/20
11:44
BCRX

BioCryst

$4.00 /

+0.05 (+1.27%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren raised the firm's price target on BioCryst Pharmaceuticals to $10 from $8 and keeps an Overweight rating on the shares. BioCryst provided several updates during the Q1 earnings call, with the most exciting being the initial BCX9930 data in three paroxysmal nocturnal hemoglobinuria patients, Van Buren tells investors in a research note. The fairly severe patients experienced significant improvements in LDH and hemoglobin following treatment with 9930 at the initial 50/100mg dose levels, says the analyst. He believes the initial PNH data suggest that 9930 may be an effective oral Factor D inhibitor.

ShowHide Related Items >><<
BCRX BioCryst
$4.00 /

+0.05 (+1.27%)

05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
03/05/20 Piper Sandler
BioCryst's berotralstat should still be approved this year, says Piper Sandler
02/18/20 JMP Securities
JMP says BioCryst should react favorably to NDA acceptance, lack of AdComm
Hot Stocks
BioCryst sees FY20 net operating cash use $125M-$150M » 07:41
05/06/20
05/06
07:41
05/06/20
07:41
BCRX

BioCryst

$3.95 /

+0.03 (+0.77%)

BioCryst expects full…

BioCryst expects full year 2020 net operating cash use to be in the range of $125 to $150 million, and its operating expenses to be in the range of $135 to $160 million. The company's operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the company's stock, as well as by the vesting of the company's outstanding performance-based stock options.

ShowHide Related Items >><<
BCRX BioCryst
$3.95 /

+0.03 (+0.77%)

05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
03/05/20 Piper Sandler
BioCryst's berotralstat should still be approved this year, says Piper Sandler
02/18/20 JMP Securities
JMP says BioCryst should react favorably to NDA acceptance, lack of AdComm

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.